Table 2. CONSORT extension checklist of ten recommendations when reporting harms in randomized controlled trials (n = 18).

Author (Year)	1	2	3	4	5	6	7*	8**	9	10
Brismee et al (2007)17				X		X	X
Hall et al (2011)16							X
Li et al (2004)33							X
Li et al (2004)32						X	X	X
Ni et al (2010)30			X	X		X	X
Shen et al (2010)45, 67	X	X	X	X			X	X		X
Taylor et al (2012)53				X			X	X
Tsang et al (2007)46, 47	X		X	X		X	X
Tsang et al (2010)48			X	X		X	X	X
Wang et al (2009)54	X					X	X
Wang et al (2010)31	X		X	X			X			X
Wayne et al (2012)49				X			X	X
Wolf et al (2003)55			X			X	X
Wolfson et al (1996)19			X	X			X
Yeh et al (2004)50			X	X			X			X
Yeh et al (2010)51			X	X			X	X		X
Yeh et al (2011)52			X	X			X	X		X
Yeung et al (2012)18	X	X		X			X			X

^*We considered study to have addressed recommendation 7 if the denominator for harms could be easily inferred from the CONSORT flow diagram or other text describing 'what follow up-time counts towards overall exposure'

^**We considered study to have addressed recommendation 8 if adverse events were further categorized per arm by type, grade, OR seriousness (where we included relatedness to the intervention as a type). If there were no events in the control arm, this needed to be stated.